European Pharmaceutical Review
JANUARY 30, 2024
The European Medicine Agency’s human medicines committee (CHMP) recommended marketing authorisations for the regulatory approval of three medicines at its January 2024 meeting last week. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.
European Pharmaceutical Review
JULY 29, 2024
These medicines were recommended by the CHMP to treat plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. The post CHMP meeting highlights – July 2024 appeared first on European Pharmaceutical Review. Tuznue (trastuzumab) for breast and gastric cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hospital Pharmacy Europe
AUGUST 13, 2024
The first version of a list of critical medicines was published in 2023, with the aim to prevent disruption and help track EU manufacturing capacity and ensure the security of supply and availability of critical medicines at the EU level.
Pharmaceutical Technology
DECEMBER 19, 2022
by the end of 2023 and may continue to rise in 2024 to 5%. Joy Polefrone, the executive director of the organization, says it aims to build a cluster of partners who are capable of manufacturing generic medicines. JP Morgan predicts that the US unemployment rate could rise to 4.3%
European Pharmaceutical Review
APRIL 30, 2024
The committee also recommended the biosimilar medicine Wezenla (ustekinumab) to treat of plaque psoriasis. Generic medicine Eribulin Baxter (eribulin) was also granted a positive opinion by the committee, to treat breast cancer and liposarcoma. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.
STAT
APRIL 23, 2025
The gambit was prompted by the penalties that companies must pay to Medicaid when they raise the price of a medicine above the inflation rate, a consequence of a provision in a federal law that went into effect in early 2024. saying it will encourage innovation , The Financial Times notes. ” The U.S. government estimates.
European Pharmaceutical Review
JULY 1, 2024
Additionally, approval was recommended two generic medicines: Enzalutamide Viatris (enzalutamide) to treat prostate cancer, and Nilotinib Accord (nilotinib) was also recommended to treat Philadelphia chromosome positive chronic myelogenous leukaemia.
Expert insights. Personalized for you.
98 
Let's personalize your content